# Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

> **NCT02065700** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 739 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Filgotinib

## Key facts

- **NCT ID:** NCT02065700
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-25
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 739 (ACTUAL)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065700, "Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02065700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*